Pesquisar
Nkarta Inc
NKTXAdicionar à lista de desejos
2.090USD
-0.060-2.79%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
149.53MValor de mercado
PerdaP/L TTM
Mais detalhes de Nkarta Inc Empresa
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Informações de Nkarta Inc
Código da empresaNKTX
Nome da EmpresaNkarta Inc
Data de listagemJul 10, 2020
CEOHastings (Paul J)
Número de funcionários157
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 10
Endereço1150 Veterans Boulevard
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone19254071049
Sitehttps://www.nkartatx.com/
Código da empresaNKTX
Data de listagemJul 10, 2020
CEOHastings (Paul J)
Executivos da empresa Nkarta Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
159.87K
-1.11%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Angela Thedinga
Ms. Angela Thedinga
Independent Director
Independent Director
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
-100.00%
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
159.87K
-1.11%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Nkarta Inc?
Os cinco principais acionistas de Nkarta Inc são: Mr. Paul J. Hastings
Quantas instituições possuem ações da Nkarta Inc (NKTX)?
Em 2026Q1, 280 instituições possuíam ações da Nkarta Inc, com valor de mercado aproximado de 58.52M, representando 82.11% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -25744153.00.